Administration of the β3-AR antagonist, SR59230A, in a murine syngeneic model of NB, reduced tumor growth to a greater extent than an anti-PD-L1 antibody mAb (αPD-L1) treatment, but no synergistic effect was observed when mice were treated with both drugs (Fig. 1A, B). This evidence concerns the gene ADRB3 and neoplasm.